



## ***Sunshine Heart appoints leading US and Australian cardiologists to Medical Advisory Board***

**Sydney, Australia. 30 June 2006:** Sunshine Heart, Inc. (ASX, SHC) today announced the strengthening of its Medical Advisory Board (MAB) with the addition of two distinguished cardiologists. Sunshine Heart's Medical Advisory Board includes eleven leading international Heart Failure cardiologists and cardiac surgeons.

The new members are **Professor Marc A. Silver**, Chairman of the Department of Medicine and Director of the Heart Failure Institute at Advocate Christ Medical Center in Oak Lawn, Illinois and Clinical Professor of Medicine at the University of Illinois School of Medicine, and **Professor David Kaye**, Associate Director and Head of the Heart Failure and Experimental Cardiology Division, Baker Heart Research Institute, Consultant Cardiologist Cardiovascular Medicine Service and Heart/Heart Lung Replacement Service at the Alfred Hospital in Melbourne and Professor of Medicine, Department of Medicine, Monash University.

Professor Kaye is internationally recognised for his research work that has led to major advances in the understanding of mechanisms responsible for the development and progression of heart failure (HF) that is directly translatable into clinical practice. He has also been instrumental in the development and application of a range of novel devices for the treatment of heart failure.

"While medication is sufficient for many patients with heart failure, there are an increasing number of patients that are experiencing persistent heart failure symptoms despite such treatment." Professor Kaye said. "For patients with moderate heart failure, devices such as Sunshine Heart's C-Pulse™ system have the potential to offer considerable improvement in quality of life".

Professor Silver is a leading specialist in the management of heart failure and was a founding member and the initial membership chairman of the Heart Failure Society of America. He has been a principal investigator in more than 70 large-scale clinical trials. Dr Silver has a long established interest in heart failure, patient care and non-pharmacologic therapy.

Professor Silver said: "Because we still recognise heart failure as a complex of disease symptoms, we are treating patients who have a very advanced disease that has outstripped the normal compensatory controls. For many of these patients, pills and pacemakers attenuate but do not control the disease process. We continue to look for novel approaches that safely, but dramatically restore homeostasis to our patients."

**For further information:** Please see [www.sunshineheart.com](http://www.sunshineheart.com) or contact

<b>Sunshine Heart</b>	<b>Media</b>
Victor Windeyer, COO +61 2 8424 7700 <a href="mailto:victor.windeyer@sunshineheart.com">victor.windeyer@sunshineheart.com</a>	Rebecca Wilson +612 9237 2800 / 0417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>
Don Rohrbaugh, CEO +1 714 665 1951 <a href="mailto:don.rohrbaugh@sunshineheart.com">don.rohrbaugh@sunshineheart.com</a>	

The shares of Sunshine Heart have not been registered under the Securities Act of 1933 (the "US Securities Act") and may not be offered, sold or delivered in the United States, or to, or for the account or benefit of, any US Person, as such term is defined in Regulation S of the US Securities Act. In addition, hedging transactions with regard to the shares may not be conducted unless in accordance with the US Securities Act.

Statements in this document that are not purely historical are forward looking statements. Various factors could cause actual results to differ materially from any forward looking statement such as the timing and outcomes of clinical results including the efficacy of products, financing availability and product sales and marketing. Whilst we believe any forward looking statement made to be reasonable as of the date hereof, we can give no assurance that our expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement.

## About Sunshine Heart:

**Sunshine Heart** (ASX: SHC) ([www.sunshineheart.com](http://www.sunshineheart.com)) is a global medical device company, committed to the commercialisation of the C-Pulse™ an implantable, non-blood contacting, mechanical heart assist device for the treatment of people with heart failure. Sunshine Heart listed on the ASX in September 2004 and has a presence in Australia, New Zealand and the United States of America.

## The C-Pulse™

The Sunshine Heart C-Pulse is an implantable, non-blood contacting mechanical heart assist device powered by an external driver unit. The C-Pulse has three main components:

**A cuff** consisting of a wrap and a balloon which is placed around the aorta just above the heart. A balloon within the cuff is inflated and deflated to the rhythm of the heart to improve blood supply to both the body and the heart muscle, while reducing the workload on the heart.

**A sensing lead** which conveys the heart's electrical signals to the external driver.

A wearable **external driver** which is linked by an air tube to the cuff and which inflates and deflates the balloon in the cuff to the rhythm of the heart.

Implantation of the C-Pulse involves wrapping the cuff around the aorta. No incisions are needed so that, unlike LVADs, the device never comes into contact with the patient's bloodstream. The C-Pulse balloon inside the cuff is designed to inflate in a way that rolls the wall of the aorta inward in a gentle 'thumb printing' manner. This mechanism achieves increased blood pumping and reduced strain on the wall of the aorta.

The balloon is inflated and deflated rhythmically to improve blood supply to the body and to assist the heart.

*Artist's rendition of C-Pulse with a wearable driver that is in development*

